Lawrence Friedhoff
- Psychiatry and Mental health top 0.5%
- Schizophrenia research and treatment 4
- Pharmacology top 0.5%
- Cholinesterase and Neurodegenerative Diseases 9
- Antibiotics Pharmacokinetics and Efficacy 7
- Treatment of Major Depression 7
- Geriatrics and Gerontology top 1%
- Neurology top 2%
- Physiology top 2%
- Alzheimer's disease research and treatments 5
-
- Computational Drug Discovery Methods 5
-
- Lipoproteins and Cardiovascular Health 4
-
- Microbial Metabolism and Applications 4
- Co-authors
- Samantha RogersSharon L. RogersMartin R. FarlowRachelle S. DoodyRichard C. MohsGeetha RamaswamyIlise LombardoStephen C. Piscitelli
- Journals
- European Neuropsychopharmacology (8 papers)Alzheimer s & Dementia (5 papers)Antimicrobial Agents and Chemotherapy (5 papers)
- Partner nations
- United StatesNew ZealandSweden
In The Last Decade
Lawrence Friedhoff
55 papers receiving 3.6k citations
Hit Papers
Peers
Comparison fields: 5 of 138
- Psychiatry and Mental health 1.5k
- Pharmacology 1.5k
- Geriatrics and Gerontology 316
- Neurology 475
- Physiology 1.1k
Countries citing papers authored by Lawrence Friedhoff
This map shows the geographic impact of Lawrence Friedhoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lawrence Friedhoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lawrence Friedhoff more than expected).
Fields of papers citing papers by Lawrence Friedhoff
This network shows the impact of papers produced by Lawrence Friedhoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lawrence Friedhoff. The network helps show where Lawrence Friedhoff may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Lawrence Friedhoff, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Safety and Efficacy of First-in-Class mtROS scavenger SkQ1 for the Treatment of Dry Eye Disease: A Phase 3 Clinical Trial | 2019 | 1 |
| 2 | 2017 | 1 | |
| 3 | 2017 | 4 | |
| 4 | 2016 | 7 | |
| 5 | 2015 | 2 | |
| 6 | DT‐01‐04: The efficacy of RVT‐101, a 5‐ht6 receptor antagonist, as an adjunct to donepezil in adults with mild‐to‐moderate Alzheimer's disease: Completer analysis of a phase 2b studybreakdown → | 2015 | 583 |
| 7 | 2011 | 54 | |
| 8 | 2002 | 23 | |
| 9 | 2002 | 9 | |
| 10 | 2002 | 32 | |
| 11 | 2001 | 86 | |
| 12 | 2000 | 69 | |
| 13 | 1999 | 481 | |
| 14 | 1997 | 7 | |
| 15 | The Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease: Results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trialbreakdown → | 1996 | 611 |
| 16 | 1995 | 6 | |
| 17 | 1992 | 3 | |
| 18 | 1986 | 12 | |
| 19 | 1984 | 16 | |
| 20 | 1976 | 6 |
About Lawrence Friedhoff
Lawrence Friedhoff is a scholar working on Pharmacology, Psychiatry and Mental health, Anesthesiology and Pain Medicine, Geriatrics and Gerontology and Filtration and Separation, having authored 55 papers that have together received 3.9k indexed citations. Recurring topics across this work include Cholinesterase and Neurodegenerative Diseases (9 papers), Antibiotics Pharmacokinetics and Efficacy (7 papers), Treatment of Major Depression (7 papers), Computational Drug Discovery Methods (5 papers), Alzheimer's disease research and treatments (5 papers), Lipoproteins and Cardiovascular Health (4 papers), Microbial Metabolism and Applications (4 papers) and Schizophrenia research and treatment (4 papers). The work is most often cited by research in Psychiatry and Mental health (1.5k citations), Pharmacology (1.5k citations), Geriatrics and Gerontology (316 citations), Neurology (475 citations) and Physiology (1.1k citations). Lawrence Friedhoff has collaborated with scholars based in United States, New Zealand and Sweden. Frequent co-authors include Samantha Rogers, Sharon L. Rogers, Martin R. Farlow, Rachelle S. Doody, Richard C. Mohs, Geetha Ramaswamy, Ilise Lombardo, Stephen C. Piscitelli, H Petit and H.‐J. Möller. Their work appears in journals such as European Neuropsychopharmacology, Alzheimer s & Dementia, Antimicrobial Agents and Chemotherapy, Critical Care Medicine and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.